CLN-049 monotherapy demonstrates promising efficacy, including multiple complete responses and encouraging response ...
LEGO will kick off 2026 with a huge slate of new releases in January that, for the time being, are headlined by sets like the ...
The release of Phase III Stage 1 data for gotistobart (BNT316/ONC-392) at NACLC 2025 marks one of the most significant ...
Indiana lawmakers are weighing a new “bell to bell” proposal that would tighten cellphone restrictions in K-12 schools by ...
ASH 2025 oral presentation on SENTI-202 in 20 Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients (18 response evaluable) shows high efficacy: 50% ORR and 42% CR/CRh (100% of CRs and 83% of ...
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and ...
New FDA guidance signals a major shift for CAR-T development, calling for randomized trials with standard-of-care control groups and clear evidence of superiority over existing therapies, while ...
If the parties keep screaming at each other while Duggan assembles his coalition, Michigan won’t elect a Democrat or a ...
PARADISE TWP. — Flanked by banners boasting of “lower prices” and “bigger paychecks,” President Donald Trump claimed to have ...
Highly encouraging early data from the ongoing Phase 1b study evaluating investigational drug GNS561 with a MEK inhibitor (MEKi) in KRAS mutated ...
A December 2024 order prompted by class actions required the US Bureau of Prisons to provide proper safeguards to prevent ...
The best PFS results we’ve ever seen in relapsed, refractory myeloma.”The combination of teclistamab (Tecvayli, Janssen) plus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback